The Effectiveness of Metformin versus Glyburide in Type 2 Diabetes: Results from ADOPT (A Diabetes Outcomes Progression Trial)

Herman, William H.; Haffner, Steven M.; Kahn, Steven E.; Zinman, Bernard; Holman, Rury R.; Viberti, Giancarlo F.; Lachin, John M.; Kravitz, Barbara G.; Heise, Mark A.
June 2007
Diabetes;Jun2007 Supplement 1, Vol. 56, pA146
Academic Journal
ADOPT compared initial oral monotherapies in recently diagnosed type 2 diabetic patients and found rosiglitazone to be superior to metformin (Met) and glyburide (Gly) as assessed by time to monotherapy failure (MF), defined as time to the first of two successive fasting plasma glucose (FPG) values >180 mg/dl. Previously, the UKPDS compared Met and sulfonylurea treatment in overweight patients (≥120% ideal body weight, mean BMI 31.4 kg/m²) and found that the A1c responses to therapy were similar. We present here the ADOPT results comparing the efficacy of Met and Gly, which was a prespecified secondary analysis. Eligible patients had type 2 diabetes diagnosed within 3 years, were 30-75 years of age, and had FPG levels between 126-180 mg/dl with lifestyle management alone. Mean BMI was 32.2 kg/m². 1454 patients were randomized to Met and 1441 to Gly. Study medication was titrated to a total daily dose of 2 g Met or 15 mg Gly. Compared to Gly, Met reduced the risk of MF by 46.5% (p<0.01). At 4 years, 36% in the Met group and 26% in the Gly group remained on monotherapy and had A1c <7% (p<0.01). From a longitudinal linear model, mean A1c <7% was maintained until the 45 month visit in the Met group and the 33 month visit in the Gly group. More Met-treated patients experienced gastrointestinal adverse events (38% vs. 22%, p<0.01) but fewer experienced hypoglycemia (12% vs. 39%, p<0.01). There was weight gain at 4 years with Gly but not with Met (1.81 kg vs -2.53 kg, p<0.01). In conclusion, ADOPT demonstrated that in recently diagnosed patients with type 2 diabetes, Met is more effective than Gly, providing more durable glycemic control with less hypoglycemia and no weight gain.


Related Articles

  • Sitagliptin, a Selective DPP-4 Inhibitor, Improves Glycemic Control when Added to a Sulfonylurea or to a Sulfonylurea and Metformin in Patients with Type 2 Diabetes. Hermansen, Kjeld; Kipnes, Mark; Luo, Edmund; Fanurik, Debra; Khatami, Hootan; Stein, Peter P. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA143 

    Efficacy and safety of sitagliptin (SITA) were examined in patients with type 2 diabetes and inadequate glycemic control (A1C 7.5% to 10.5%) on glimepiride (G) alone or G plus metformin (G+MF). After a titration/stabilization period on G (≥4 mg/day) ± MF (≥ 1500 mg/day) and a...

  • Pramlintide Improved Glycemic Control and Reduced Body Weight in Patients With Type 2 Diabetes Treated With Basal Insulin (Without Mealtime Insulin) and a Thiazolidinedione. Lorenzi, Gayle; Frias, Juan; Lutz, Karen; Kesty, Nicole; Zhang, Bei; Kolterman, Orville // Diabetes;Jun2007 Supplement 1, Vol. 56, pA147 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, improves glycemic control and body weight in patients with type 2 diabetes (T2DM) treated with insulin with or without sulfonylurea (SFU) and/or metformin (MET). Its efficacy and safety as an adjunct to insulin+thiazolidinedione...

  • Diabetes treatment without weight gain.  // Pharmaceutical Technology Europe;Sep2006, Vol. 18 Issue 9, p16 

    The article reports on the presentation of the results of a clinical trial of Levemir, a novel diabetes drug, at the American Diabetes Association congress in Washington D.C. In a study of more than 1,000 people, Levemir showed promising results for diabetes control without weight gain. The drug...

  • Insulin Myths and Facts.  // Clinical Diabetes;Winter2007, Vol. 25 Issue 1, p39 

    The article presents information on several myths and facts about insulin. The indication of using insulin as a failure of diabetes management is a myth. Diabetes is considered as an insulin problem not as many people think that it is a sugar problem. Weight gain could be experience by patients...

  • Long-acting insulin analogues do not improve glycemic control but do reduce nocturnal hypoglycemia in diabetes. Smith, Steven A.; Murad, M. Hassan // ACP Journal Club;Mar/Apr2008, Vol. 148 Issue 2, p11 

    The article focuses on 34 randomized controlled trials (RCTs) investigating the efficacy of long-acting insulin analogues (LAIAs) compared with human insulin or oral antidiabetic agents in patients with diabetes mellitus. Trials found out that LAIAs do not reduce Hemoglobin A[sub 1c] levels more...

  • Review: long-acting insulin analogues do not improve glycaemic control but reduce nocturnal hypoglycaemia. Tran, K. // Evidence Based Medicine;Jun2008, Vol. 13 Issue 3, p79 

    QUESTION In patients with diabetes mellitus, what is the efficacy of long acting insulin analogues (LAIAs) compared with human insulin or oral antidiabetic agents? REVIEW SCOPE Studies selected compared LAIAs (insulin glargine or insulin detemir) with conventional human insulin (including...

  • Hypoglycemia: Still the Limiting Factor in the Glycemic Management of Diabetes. Philip Cryer // Endocrine Practice;Sep2008, Vol. 14 Issue 6, p750 

    Objective: To review the prevalence of, risk factors for, and prevention of hypoglycemia from the perspective of the pathophysiologic aspects of glucose counterregulation in diabetes.Methods: This review is based on personal experience and research and the relevant literature.Results: Although...

  • Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus. Rajagopalan, Rukmini; Perez, Alfonso; Ye, Zhan; Khan, Mehmood; Murray, Frederick T. // Drugs & Aging;2004, Vol. 21 Issue 4, p259 

    Pioglitazone as monotherapy and in combination with sulfonylurea, metformin, or insulin has consistently demonstrated improved glycaemic and lipid parameters in patients with type 2 diabetes mellitus. Objective: We performed a subanalysis to examine the effect of pioglitazone on glycaemia and...

  • Clinical pharmacokinetics: brief reports.  // Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p16 

    Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics